Oncology Drug Approval - Accelerated

Bridging the gap between biomarkers and In Vitro Companion Diagnostics

Assay Menu By Disease

MolecularMD employs gold-standard and cutting-edge Technologies & Platforms in creating its high-performance assays. Below are listed our validated research and diagnostic assays. For information about other biomarkers and custom assay design capabilities, contact MolecularMD.

{mooblock=CML Targeted Therapy Management }

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate CML Targeted Therapy Management and potential monitoring of treatment efficacy.

  • RT-qPCR BCR-ABL1 (p210)
  • RT-qPCR BCR-ABL1 (p190)
  • BCR-ABL1 Mutation Anaysis
  • BCR-ABL1 Mutation NGx-Profiler

{/mooblock}

{mooblock=GIST Targeted Therapy Management }

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate GIST Targeted Therapy Management and potential monitoring of treatment efficacy.

  • c-KIT Mutation Analysis (Exons 9,11,13,17,18)
  • PDGFRa Mutation Analysis (Exons 12,14, 18)
  • c-KIT Expression Analysis

{/mooblock}

{mooblock=Melanoma Targeted Therapy Management }

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate Melanoma Targeted Therapy Management and potential monitoring of treatment efficacy.

  • BRAF Mutation Analysis (Exon 15)
  • BRAF Mutation Analysis (V600E/K)
  • NRAS Mutation Analysis (Exons 1,2)
  • NRAS Mutation Analysis (Q61R/K/L)
  • c-KIT Mutation Analysis (Exons 9, 10, 11, 13, 17, 18)

{/mooblock}

{mooblock=Lung Cancer Targeted Therapy Management }

The MolecularMD Clinical Laboratory offers the following sensitive, reproducible and highly specific mutation analysis and expression analysis testing to aid in patient selection for appropriate Lung Cancer Targeted Therapy Management and potential monitoring of treatment efficacy.

  • ALK Mutation Analysis (Exons 22, 23, 24, 25)
  • EGFR T790M Plasma Test
  • c-MET Expression Analysis
  • E-cadherin Expression Analysis
  • KRAS Mutation (G12D/A/V/S/R, G13D, Q61L/R/H)
  • Vimentin Expression Analysis
  • Hsp70 Expression Analysis
  • EGFR T790M Resistant Mutation NGx-Profiler

{/mooblock}

Related Services:

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes